PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1), commonly known as p85α, is the major regulatory subunit of class IA phosphoinositide 3-kinases (PI3Ks). This critical signaling protein plays essential roles in cellular growth, survival, metabolism, and synaptic function. Dysregulation of p85α and PI3K/Akt signaling is strongly implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and stroke. This page provides comprehensive information about p85α structure, function, and its involvement in neurodegeneration.
| | |
|---|---|
| **Protein Name** | Phosphoinositide-3-Kinase Regulatory Subunit 1 (p85α) |
| **Gene Symbol** | [PIK3R1](/genes/pik3r1) |
| **UniProt ID** | [P27986](https://www.uniprot.org/uniprot/P27986) |
| **Molecular Weight** | 85 kDa |
| **Amino Acids** | 724 |
| **Subcellular Localization** | Cytoplasm, plasma membrane, endosomes |
| **Protein Family** | PI3K regulatory subunit (p85) family |
| **Brain Expression** | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Cerebellum, Basal ganglia |
| **PDB Structure** | [4A0B](https://www.ebi.ac.uk/pdbe/entry/pdb/4A0B), [4JPS](https://www.ebi.ac.uk/pdbe/entry/pdb/4JPS), [4OVU](https://www.ebi.ac.uk/pdbe/entry/pdb/4OVU) |
p85α is encoded by the PIK3R1 gene and serves as the principal regulatory subunit of class IA PI3Ks. The protein regulates the catalytic p110 subunit (p110α, p110β, p110δ) by controlling its localization, stability, and enzymatic activity. p85α contains multiple protein-protein interaction domains that allow it to couple activated cell surface receptors to intracellular signaling cascades.
¶ Domain Architecture
p85α (724 amino acids) contains several distinct domains:
- N-terminal SH3 domain (1-85): Binds proline-rich sequences via PXXP motifs
- Bcr homology domain (85-300): Contains the inter-SH2 (iSH2) region critical for p110 binding
- iSH2 domain (300-500): Forms the main interface with p110 catalytic subunit
- C-terminal SH2 domain (cSH2) (600-620): Binds phosphotyrosine motifs on activated receptors
- N-terminal SH2 domain (nSH2) (330-420): Regulates p110 activity
- Molecular weight: ~85 kDa
- Isoforms: p85α, p55α (pik3r1 splice variant), p50α
- Post-translational modifications: Phosphorylation (Y459, Y467), ubiquitination
¶ PI3K Activation and Regulation
p85α is essential for PI3K function:
- Receptor recruitment: SH2 domains bind phosphorylated tyrosine residues on activated RTKs (e.g., insulin receptor, EGFR, PDGFR)
- p110 recruitment: iSH2 domain brings the p110 catalytic subunit to the membrane
- Autoinhibition release: p85α relieves p110 autoinhibition, enabling PIP2 phosphorylation
- PIP3 production: p110 converts PIP2 to PIP3, a key second messenger
- PI3K/Akt pathway: Major downstream effector of p85α-regulated PI3K
- mTOR pathway: Akt activates mTORC1 for protein synthesis
- GSK-3β regulation: Akt phosphorylates and inhibits GSK-3β
- FOXO transcription factors: Akt phosphorylates FOXO, promoting its cytoplasmic retention
- Cell survival: Akt-mediated inhibition of pro-apoptotic proteins (Bad, caspase-9)
- Metabolism: Insulin signaling, GLUT4 translocation, lipid synthesis
- Protein synthesis: mTORC1 activation
- Cell growth: Ribosome biogenesis and translation
- Synaptic plasticity: NMDA receptor trafficking, AMPA receptor insertion
- Neuronal survival: Neurotrophic factor signaling (BDNF, NGF)
- Synaptic plasticity: Long-term potentiation (LTP) and memory formation
- Metabolic regulation: Neuronal glucose uptake
- Axonal guidance: Growth cone dynamics
p85α and PI3K signaling are prominently affected in AD:
- Reduced p85α expression: Decreased levels in AD hippocampus and cortex
- Impaired Akt signaling: Downstream of p85α, Akt activity is reduced
- Tau pathology: PI3K/Akt normally inhibits GSK-3β; loss promotes tau hyperphosphorylation
- Amyloid-beta effects: Aβ disrupts insulin-PI3K-Akt signaling
- Synaptic failure: PI3K is critical for synaptic plasticity; dysfunction contributes to memory deficits
- Neuronal survival: Reduced neuroprotection against Aβ toxicity
- Dopaminergic neuron survival: PI3K/Akt is critical for nigral neuron survival
- LRRK2 interactions: Pathogenic LRRK2 affects PI3K pathway signaling
- α-Synuclein pathology: PI3K/Akt dysfunction may sensitize neurons to α-synuclein toxicity
- Neurotrophic factors: GDNF signaling relies on PI3K/Akt
- Motor neuron survival: PI3K/Akt pathway promotes motor neuron viability
- Glutamate excitotoxicity: PI3K signaling can counteract excitotoxic cell death
- Mitochondrial function: PI3K helps maintain mitochondrial health
¶ Stroke and Ischemia
- Ischemic preconditioning: PI3K/Akt activation is neuroprotective
- Reperfusion injury: PI3K signaling can reduce oxidative damage
- Angiogenesis: PI3K promotes blood vessel formation post-stroke
- Type 2 diabetes link: p85α mutations/dysfunction may increase AD risk
- Insulin resistance: Brain insulin signaling impairment in both T2D and AD
| Drug/Compound |
Target |
Development Stage |
Potential Use |
| Wortmannin |
PI3K (irreversible) |
Research tool |
Lab studies |
| LY294002 |
PI3K (reversible) |
Research tool |
Lab studies |
| Idelalisib |
p110δ |
Approved (oncology) |
Under investigation |
| Alpelisib |
p110α |
Approved (oncology) |
May benefit brain |
| Metformin |
AMPK activation |
Approved (diabetes) |
Under investigation for AD |
- Broad pathway effects: Systemic PI3K inhibition causes metabolic dysfunction
- Blood-brain barrier: Drug delivery to CNS is challenging
- Biphasic effects: Constitutive activation can be oncogenic
- p85α modulators: Developing compounds that enhance p85α function
- Akt activators: Direct Akt activation bypasses p85 dysfunction
- Neurotrophic factors: BDNF mimetics that activate PI3K
- Cantley LC (2002). "The phosphoinositide 3-kinase pathway." Science. 296(5573): 1655-1657. PMID:11967143
- Hers I, et al. (2011). "PI3K in neuronal cells." J Neurochem. 119(2): 251-266. PMID:21418177
- Zhang H, et al. (2022). "PI3K/Akt dysfunction in Alzheimer's disease." Mol Neurobiol. 59(2): 1144-1159.
- Bassil F, et al. (2021). "PI3K signaling in Parkinson's disease." Cell Mol Neurobiol. 41(5): 911-924.
- Baek JH, et al. (2020). "p85α deficiency in neurons." J Neurosci. 40(41): 7853-7869.
- Liu Y, et al. (2019). "PI3K/Akt in stroke neuroprotection." Neurochem Res. 44(10): 2270-2280.
- Moloney AM, et al. (2010). "Defects in IGF-1 and PI3K signaling." J Alzheimers Dis. 20(2): 549-560.
The study of Pik3R1 Protein P85Α has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.